Interim analysis of the SEQUENCE open-label extension: in 224 patients with Crohn's disease and prior anti-TNF failure, clinical remission on risankizumab stayed at ≥74.5% (as observed) through Week 100; serious adverse events were 11.8/100 patient-years.
RCTn = 224
Peyrin-Biroulet et al. Efficacy and safety of risankizumab in patients with moderately to severely active Crohn's disease: interim results from the SEQUENCE open-label extension study